Cell surface biotinylation to identify the receptors involved in nanoparticle uptake into endothelial cells

Investigation on topology-dependent adsorption and aggregation of protein on nanoparticle surface enabled by integrating time-limited proteolysis with cross-linking mass spectrometry

The biological identity of nanomaterials is predominantly dictated by their surface protein corona (PC), yet the topological characteristics of most PCs remain uncharacterized in situ. We employed time-limited proteolysis combined time-segmented cross-linking mass spectrometry at specific intervals (10 min, 1 h, 2 h, 4 h and 18 h) to, for the first time, elucidate the spatial distribution, topological architecture and molecular orientation of multiple proteins within the multi-layered PC on nano-Fe3O4 surfaces. Additional monolinks, intermolecular and intramolecular crosslinks which were previously inaccessible to the crosslinker were unveiled in a layer-by-layer manner. 197 sparse intermolecular crosslinks involving 368 distinct wheat proteins were identified. Notably, charge complementarity and hydrophobic residue pairings, rather than hydrophobic peptide motifs, primarily govern the protein-protein interactions. For the crosslinks bridging the proteolysable and proteolysis-resistant layers, 72 % presented one end in a random coil conformation. Furthermore, the molecular orientation of 16 proteins including Q8L803, P11534 and P93594, etc., in the proteolysis-resistant layer was determined. The observation of violated intramolecular crosslinks between two rigid structural domains (e.g., A0A3B5Y430) suggests that nanoparticle-protein and protein-protein interactions may induce conformational changes in the adsorbed proteins. These findings offer novel insights into the spontaneous formation mechanisms of PC.

The pathogenic APP N-terminal Val225Ala mutation alters tau protein liquid-liquid phase separation and exacerbates synaptic damage

Amyloid precursor protein (APP) is predominantly located in synapses of neurons and its mutations have been well recognized as the most important genetic causal factor for the familial Alzheimer's disease (AD). While most disease-causal mutations of APP occur within the Aβ-coding region or immediately proximal, the pathological impacts of mutations in the N-terminus of APP protein, which remote from the Aβ sequence, on neuron and synapse are still largely unknown. It was recently reported a pathogenic APP N-terminal Val225Ala mutation (APPV225A) with clinically featuring progressive dementia and typical AD pathologies in brain. In our present study, we further found that APPV225A mutation alters the N-terminal structure of APP, which enhances its binding affinity to tau protein and significantly increases APP-mediated endocytosis. Consequently, APPV225A promotes the uptake of extracellular tau into SH-SY5Y cells, further linking the structural change in APP to intracellular tau accumulation. In addition, APPV225A also notably alters the liquid-liquid phase separation (LLPS) of intracellular tau and intensified tau phosphorylation and aggregation in SH-SY5Y cells. Moreover, APPV225A promote AD-like tau pathology and synaptic damages in human induced pluripotent stem cells (hiPSCs)-derived neural progenitor cells and neurons, as well as in hiPSCs-derived human brain organoids and mouse brain, which can be ameliorated by tau knockdown. Proximity labeling identified several key APPV225A-interacting proteins, including HS3ST3A1, which was shown to directly regulate tau LLPS and phosphorylation. These findings nicely build on our previous work on roles for APP in tau-related pathological phenotypes and further highlight the involvement of N-terminal APP as the key region for both amyloidopathy and tauopathy, two aspects of AD pathogenesis and progression. Our study may also provide a theoretical breakthrough for AD therapy and highlight the important hub roles of APP and making previously neglected N-terminal APP as a potential target for the discovery of novel disease-modifying therapeutic agents against AD, holding significant scientific values and clinical promise.

Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium

Endothelial cells (ECs) are pivotal in maintaining vascular health, regulating hemodynamics, and modulating inflammatory responses. Nanocarriers hold transformative potential for precise drug delivery within the vascular system, particularly targeting ECs for therapeutic purposes. However, the complex interactions between vascular ECs and nanocarriers present significant challenges for the development and clinical translation of nanotherapeutics. This review assesses recent advancements and key strategies in employing nanocarriers for drug delivery to vascular ECs. It suggested that through precise physicochemical design and surface modifications, nanocarriers can enhance targeting specificity and improve drug internalization efficiency in ECs. Additionally, we elaborated on the applications of nanocarriers specifically designed for targeting ECs in the treatment of cardiovascular diseases, cancer metastasis, and inflammatory disorders. Despite these advancements, safety concerns, the complexity of in vivo processes, and the challenge of achieving subcellular drug delivery remain significant obstacles to the effective targeting of ECs with nanocarriers. A comprehensive understanding of endothelial cell biology and its interaction with nanocarriers is crucial for realizing the full potential of targeted drug delivery systems.

CAG peptide functionalized graphene quantum dots-cationic polymer composite gene carriers

In this study, a targeted graphene quantum dot-cationic polymer composite gene vector with endothelial cell-targeting CAG peptide was successfully designed and prepared. This vector could efficiently bind and deliver the therapeutic gene pZNF580 to endothelial cells (HUVECs). At a concentration of less than 40 μg mL-1, the results of the CCK-8 assay showed that the relative cell viability of each composite gene vector was greater than 80%, and the results of the flow cytometry assay showed that C-GQDs-PEI-PEG-CAG/pZNF580 (88.96%) and N-GQDs-PEI-PLGA-PEG-CAG/pZNF580 (87.70%) treated groups showed significantly higher cell viability than the positive control group Lip2000/pZNF580 (56.76%). The results of in vitro cell transfection and western blot experiments confirmed that the composite gene vector was able to deliver pZNF580 efficiently and enable the high expression of the ZNF580 protein in HUVECs. The results of the EdU assay, wound healing and Transwell experiments indicated that the composite gene vector/pZNF580 nanoparticles (NPs) could significantly promote the proliferation and migration. The results of the EdU method showed that the proliferative ability of C-GQDs-PEI-PLGA/pZNF580 (84.96 ± 1.99%) and N-GQDs-PEI-PLGA/pZNF580 (85.01 ± 1.31%) treatment groups for HUVECs was significantly higher than that of the positive control group Lip2000/pZNF580 (77.89 ± 2.18%). The results of the scratch assay showed that the cell migration rate of C-GQDs-PEI-PLGA-PEG-CAG/pZNF580 (93.08 ± 1.97%) and N-GQDs-PEI-PLGA-PEG-CAG/pZNF580 (91.99 ± 1.52%) groups was significantly higher than that of the positive control group Lip2000/pZNF580 (85.03 ± 2.21%). In addition, the results of the in vitro angiogenesis assay showed that the C-GQDs-PEI-PLGA-PEG-CAG/pZNF580 and N-GQDs-PEI-PLGA-PEG-CAG/pZNF580 groups had significantly higher angiogenesis-promoting ability than the positive control group, Lip2000/pZNF580.The present study provides a highly efficient and low-toxic method to promote endothelial cell migration in the field of regenerative medicine and a low-toxicity strategy to promote endothelial layer formation, which provides new possibilities for future vascular regeneration therapy.

The biomolecular corona of nanomedicines: effects on nanomedicine outcomes and emerging opportunities

Upon administration, nanomedicines adsorb a corona of endogenous biomolecules on their surface, which can affect nanomedicine interactions with cells, targeting, and efficacy. While strategies to reduce protein binding are available, the high selectivity of the adsorbed corona is enabling novel applications, such as for biomarker discovery and rare protein identification. Additionally, the adsorbed molecules can promote interactions with specific cell receptors, thus conferring the nanomedicine new endogenous targeting capabilities. This has been reported for Onpattro, a lipid nanoparticle targeting the hepatocytes via apolipoproteins in its corona. Recently, selective organ-targeting (SORT) nanoparticles have been proposed, which exploit corona-mediated interactions to deliver nanoparticles outside the liver. Strategies for corona seeding and corona engineering are emerging to increase the selectivity of similar endogenous targeting mechanisms.

The interaction between particles and vascular endothelium in blood flow

Particle-based drug delivery systems have shown promising application potential to treat human diseases; however, an incomplete understanding of their interactions with vascular endothelium in blood flow prevents their inclusion into mainstream clinical applications. The flow performance of nano/micro-sized particles in the blood are disturbed by many external/internal factors, including blood constituents, particle properties, and endothelium bioactivities, affecting the fate of particles in vivo and therapeutic effects for diseases. This review highlights how the blood constituents, hemodynamic environment and particle properties influence the interactions and particle activities in vivo. Moreover, we briefly summarized the structure and functions of endothelium and simulated devices for studying particle performance under blood flow conditions. Finally, based on particle-endothelium interactions, we propose future opportunities for novel therapeutic strategies and provide solutions to challenges in particle delivery systems for accelerating their clinical translation. This review helps provoke an increasing in-depth understanding of particle-endothelium interactions and inspires more strategies that may benefit the development of particle medicine.